COLL
Collegium Pharmaceutical Inc
Halal Rating :
Last Price
$33.32
Last updated:
Market Cap
-
7D Change
-1.41%
1 Year Change
-0.58%
Company Overview
Industries
Exchange
Next Earnings Date
Collegium Pharmaceutical Inc is a specialty pharmaceutical company focused on developing and commercializing innovative pain management treatments. The company's main product portfolio includes treatments for chronic pain management, with a focus on abuse-deterrent formulations. Their key products include Xtampza® ER, an abuse-deterrent, extended-release oxycodone product, and Nucynta®, a pain management medication.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $159.3m | $147.0m | - | $22.54m | 0.00% | 15.33% |
| June 30, 2024 | $145.28m | $120.58m | - | $22.77m | 0.00% | 18.89% |
| March 31, 2024 | $144.92m | $112.79m | - | $17.34m | 0.00% | 15.37% |
Company Impact
Help us evaluate Collegium Pharmaceutical Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.